金斯瑞生物科技联营公司将发布CARVYKTI最新资料

财中社
Yesterday

  5月23日,金斯瑞生物科技(01548)发布公告,公司的联营公司传奇生物科技股份有限公司将于2025年美国临床肿瘤学会及欧洲血液学协会年会上发布用于治疗多发性骨髓瘤患者的CARVYKTI最新资料。

  该公告指出,传奇生物已于2025年5月22日向美国证券交易委员会提交了6-K表格,宣布将在上述会议上公布CARTITUDE临床开发项目的最新进展。

  此次发布的信息将为投资者提供重要的临床研究进展,帮助评估CARVYKTI的治疗效果,尤其是在多发性骨髓瘤患者中的应用。公司提醒股东及潜在投资者注意投资风险,并在买卖公司证券时保持谨慎。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10